Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
– Topline data expected Mid-Year –
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of intravenous single ascending doses of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US-based, multi-site, placebo-controlled study will enroll up to forty patients in up to five cohorts.
“We are excited to announce the continued advancement of Gemini with the dosing of our first patient in the PRIME study,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to a rapid enrollment and positive outcome of this study to bring Gemini one step closer to helping patients in need.”
Top-line data comprising safety, tolerability, and key biomarkers of activity including attenuation of the inflammatory response are expected by mid-year. Data from the PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?